We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update.
- Authors
Scott, S A; Sangkuhl, K; Stein, C M; Hulot, J‐S; Mega, J L; Roden, D M; Klein, T E; Sabatine, M S; Johnson, J A; Shuldiner, A R
- Abstract
Cytochrome P450 (CYP)2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and CYP2C19 loss-of-function alleles impair formation of active metabolites, resulting in reduced platelet inhibition. In addition, CYP2C19 loss-of-function alleles confer increased risks for serious adverse cardiovascular (CV) events among clopidogrel-treated patients with acute coronary syndromes (ACSs) undergoing percutaneous coronary intervention (PCI). Guideline updates include emphasis on appropriate indication for CYP2C19 genotype-directed antiplatelet therapy, refined recommendations for specific CYP2C19 alleles, and additional evidence from an expanded literature review (updates at http://www.pharmgkb.org).
- Subjects
PHARMACOGENOMICS; CYTOCHROME P-450; BIOTRANSFORMATION (Metabolism); CLOPIDOGREL; PLATELET aggregation inhibitors; PRODRUGS; ALLELES
- Publication
Clinical Pharmacology & Therapeutics, 2013, Vol 94, Issue 3, p317
- ISSN
0009-9236
- Publication type
Article
- DOI
10.1038/clpt.2013.105